Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension

Intravenous bevacizumab decreased mucosal bleeding in some patients with hereditary hemorrhagic telangiectasia (HHT). We treated a 47-year-old male who had HHT, severe epistaxis, and gastrointestinal bleeding, alcoholic cirrhosis, and portal hypertension with intravenous bevacizumab 2.5 mg/kg every...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoli, Luigi F., Lee, Pauline L., Lallone, Lauren, Barton, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471789/
https://www.ncbi.nlm.nih.gov/pubmed/28626375
http://dx.doi.org/10.1159/000475748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471789/
https://www.ncbi.nlm.nih.gov/pubmed/28626375
http://dx.doi.org/10.1159/000475748

Ejemplares similares